Galectin Therapeutics (NASDAQ:GALT) Receives “Neutral” Rating from HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Galectin Therapeutics (NASDAQ:GALT) in a research report sent to investors on Wednesday morning,Benzinga reports.

Separately, StockNews.com cut Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, December 30th.

Galectin Therapeutics Trading Up 4.8 %

Shares of Galectin Therapeutics stock opened at $1.32 on Wednesday. Galectin Therapeutics has a 52 week low of $0.73 and a 52 week high of $4.27. The company’s 50-day moving average price is $1.46 and its two-hundred day moving average price is $1.95. The stock has a market cap of $82.85 million, a PE ratio of -1.81 and a beta of 0.69.

Galectin Therapeutics (NASDAQ:GALT) last released its earnings results on Monday, March 31st. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). On average, equities analysts predict that Galectin Therapeutics will post -0.73 EPS for the current fiscal year.

Institutional Trading of Galectin Therapeutics

Large investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. acquired a new position in Galectin Therapeutics during the fourth quarter valued at $26,000. Inspire Advisors LLC grew its stake in Galectin Therapeutics by 86.3% during the 4th quarter. Inspire Advisors LLC now owns 21,095 shares of the company’s stock valued at $27,000 after acquiring an additional 9,772 shares in the last quarter. HighTower Advisors LLC acquired a new position in shares of Galectin Therapeutics in the 4th quarter valued at about $29,000. Two Sigma Securities LLC purchased a new stake in shares of Galectin Therapeutics in the fourth quarter worth approximately $37,000. Finally, Barclays PLC boosted its holdings in shares of Galectin Therapeutics by 309.0% during the third quarter. Barclays PLC now owns 28,587 shares of the company’s stock worth $79,000 after purchasing an additional 21,598 shares during the period. 11.68% of the stock is owned by institutional investors and hedge funds.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.